6d3g

Publication Abstract from PubMed

The diazabicyclooctane (DBO) avibactam (AVI) reversibly inactivates most serine-beta-lactamases. Previous investigations showed that inhibition constants of AVI toward class A PER-2 are reminiscent of values observed for class C and D beta-lactamases (i.e., k 2/K of approximately 10(3) M(-1) s(-1)) but lower than other class A beta-lactamases (i.e., k 2/K = 10(4) to 10(5) M(-1) s(-1)). Herein, biochemical and structural studies were conducted with PER-2 and AVI to explore these differences. Furthermore, biochemical studies on Arg220 and Thr237 variants with AVI were conducted to gain deeper insight into the mechanism of PER-2 inactivation. The main biochemical and structural observations revealed the following: (i) both amino-acid substitutions in Arg220 and the rich hydrophobic content in the active site hinder the binding of catalytic waters and acylation, impairing AVI inhibition; (ii) movement of Ser130 upon binding of AVI favors the formation of a hydrogen bond with the sulfate group of AVI; and (iii) the Thr237Ala substitution alters the AVI inhibition constants. The acylation constant (k 2/K) of PER-2 by AVI is primarily influenced by stabilizing hydrogen bonds involving AVI and important residues such as Thr237 and Arg220. (Variants in Arg220 demonstrate a dramatic reduction in k 2/K) We also observed that displacement of Ser130 side chain impairs AVI acylation, an observation not made in other extended-spectrum beta-lactamases (ESBLs). Comparatively, relebactam combined with a beta-lactam is more potent against Escherichia coli producing PER-2 variants than beta-lactam-AVI combinations. Our findings provide a rationale for evaluating the utility of the currently available DBO inhibitors against unique ESBLs like PER-2 and anticipate the effectiveness of these inhibitors toward variants that may eventually be selected upon AVI usage.

Structural Insights into the Inhibition of the Extended-Spectrum beta-Lactamase PER-2 by Avibactam.,Ruggiero M, Papp-Wallace KM, Brunetti F, Barnes MD, Bonomo RA, Gutkind G, Klinke S, Power P Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: AAC.00487-19. doi:, 10.1128/AAC.00487-19. Print 2019 Sep. PMID:31235626^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.